Bacteriophage Therapy - Global Strategic Business Report

The global market for Bacteriophage Therapy was valued at US$1.3 Billion in 2025 and is projected to reach US$1.6 Billion by 2032, growing at a CAGR of 3.0% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Bacteriophage Therapy Market - Key Trends & Drivers Summarized

Why Is Bacteriophage Therapy Re-Emerging as a Promising Alternative Amid the Global Antimicrobial Resistance Crisis?

Bacteriophage therapy - using viruses that selectively infect and destroy bacterial cells - is gaining renewed momentum as a viable alternative to traditional antibiotics, especially in the fight against multidrug-resistant (MDR) infections. As antimicrobial resistance (AMR) escalates into a global public health emergency, with conventional antibiotics becoming less effective against evolving pathogens, phage therapy offers a highly targeted approach that bypasses the collateral damage to the host microbiome and minimizes the risk of resistance proliferation.

Phages can be custom-tailored to specific bacterial strains, making them especially valuable for treating chronic, biofilm-associated, or hospital-acquired infections such as Pseudomonas aeruginosa, Acinetobacter baumannii, and MRSA. Unlike broad-spectrum antibiotics, phage therapy preserves beneficial bacteria and can be used in combination with antibiotics for synergistic effects. The resurgence of interest is also being catalyzed by landmark compassionate use cases, regulatory openness to personalized therapies, and the growing urgency to expand the infectious disease treatment arsenal beyond chemically synthesized drugs.

How Are Genomic Tools, Synthetic Biology, and Regulatory Frameworks Advancing Phage Therapy Development?

Cutting-edge tools in genomics and synthetic biology are revolutionizing the development and precision of phage therapeutics. Whole-genome sequencing allows rapid identification of lytic phages and eliminates candidates with undesirable traits such as lysogeny or toxin genes. CRISPR and other gene editing techniques are being used to engineer phages with enhanced infectivity, broader host ranges, and resistance-mitigating capabilities. These bioengineered phages can target biofilm-producing pathogens, modulate host immune responses, and deliver therapeutic payloads in complex infection sites.

Regulatory interest in flexible approval pathways - especially for personalized and compassionate use therapies - is accelerating clinical adoption. Agencies like the U.S. FDA and European Medicines Agency (EMA) are supporting investigational new drug (IND) applications and encouraging innovation through orphan drug designations and adaptive trial designs. Additionally, the establishment of phage banks and production platforms capable of rapid isolation and GMP-grade manufacturing is enabling scalable, standardized development models - bridging the gap between experimental treatment and broader commercialization.

Where Is Demand for Bacteriophage Therapy Growing and Which Applications Are Leading Clinical Focus?

Demand for bacteriophage therapy is growing globally, with active research hubs in the United States, Europe (notably Belgium, Poland, and France), Russia, and increasingly in Asia-Pacific countries such as India and South Korea. Clinical trials are expanding across therapeutic areas such as cystic fibrosis-associated infections, diabetic wound care, gastrointestinal disorders, and urinary tract infections (UTIs), where antibiotic failure rates are particularly high. Hospitals and academic centers are piloting phage therapy in ICU settings, burn units, and immunocompromised patient care as part of salvage treatments.

Pharmaceutical and biotech firms are also targeting phage therapy for applications in agriculture and veterinary medicine, where overuse of antibiotics in livestock has accelerated resistance concerns. In parallel, microbiome restoration and targeted gut decolonization are emerging as novel frontiers for phage-based therapeutics. The food safety and sanitation sectors are exploring phage preparations as natural antibacterials to control pathogens like Listeria and Salmonella - opening non-clinical avenues for phage adoption.

What Is Fueling the Global Growth of the Bacteriophage Therapy Market?

The global growth of the bacteriophage therapy market is fueled by the urgent demand for alternative antimicrobials, advances in precision biology, and expanding public and private investment in AMR solutions. Supportive regulatory sentiment, rising venture capital in phage biotech startups, and international collaborations - such as the Phage Directory and Global Phage Initiative - are building a framework for innovation, clinical validation, and eventual market scalability. High-profile case studies demonstrating phage efficacy where antibiotics failed are further reinforcing public and medical interest.

Challenges such as narrow host range, regulatory complexity, and limited large-scale trial data remain, but are being actively addressed through personalized phage cocktails, bioinformatics-driven matching algorithms, and GMP-compliant phage manufacturing ecosystems. As AMR continues to threaten modern healthcare foundations, a pivotal question defines the path ahead: Can bacteriophage therapy evolve from last-resort intervention to front-line precision antimicrobial - integrating into clinical guidelines, manufacturing pipelines, and health system protocols as a next-generation solution to the antibiotic resistance crisis?

Report Scope

The report analyzes the Bacteriophage Therapy market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Targeted Bacteria (E. Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella, Other Targeted Bacterias); Disease Indication (Urinary Tract Infections, Chronic Otitis, Dental Extraction, Chronic Ulcerative Colitis, Bone Infection, Wound & Skin Infections, Cystic Fibrosis, Other Disease Indications); Administration Route (Oral, Topical, Parenteral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the E. Coli segment, which is expected to reach US$385.3 Million by 2032 with a CAGR of a 2.3%. The Staphylococcus Aureus segment is also set to grow at 3.8% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $351.1 Million in 2025, and China, forecasted to grow at an impressive 5.0% CAGR to reach $304.9 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Bacteriophage Therapy Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Bacteriophage Therapy Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Bacteriophage Therapy Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Adaptive Phage Therapeutics, Armata Pharmaceuticals, Inc., BiomX Ltd., Biochimpharm, ContraFect Corporation and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Bacteriophage Therapy market report include:

• Adaptive Phage Therapeutics
• Armata Pharmaceuticals, Inc.
• BiomX Ltd.
• Biochimpharm
• ContraFect Corporation
• Eligo Bioscience
• Eliava Biopreparations Ltd.
• Enbiotix, Inc.
• Fixed-Phage Ltd.
• InnoPhage Ltd.
• Intralytix, Inc.
• iNtODEWorld, Inc.
• Locus Biosciences, Inc.
• Micreos BV
• Microgen
• Nextbiotics
• OPTIPHARM Co., Ltd.
• PhagePro, Inc.
• Phagelux, Inc.
• Pherecydes Pharma

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.